Mayo Clinic Laboratories > Oncology > Lung cancer

Lung cancer

Comprehensive diagnostic, prognostic, and predictive testing

Mayo Clinic Laboratories innovates at the speed of medical advancement and offers comprehensive options for diagnostic, prognostic, and predictive lung cancer testing. We’ve optimized our specimen requirements to conserve tissue, which makes results available for more patients.

Results interpretation by Mayo Clinic physicians with expertise in pulmonary oncology enables reports that integrate patient information with supporting references. This provides patient-specific context and a better understanding of the treatment path ahead.

Next-generation sequencing Next-generation sequencing
Next-generation sequencing

Our portfolio of genetic sequencing evaluations includes assessment of mutations and rearrangements in genes most commonly associated with cancer. For patients who’ve relapsed after an initial therapeutic response to EGFR-targeted therapies, we offer cell-free mutation analysis to identify acquired variations in the ETRG gene.   

Immunotherapy Immunotherapy
Immunotherapy

Mayo Clinic Laboratories offers four PD-L1 clones for assessing patient response to specific immunotherapies, which have emerged as a therapeutic option for certain patients with non-small cell lung cancer.

News and updates

The latest

Dr. Dong Chen and Dr. Sounak Gupta join Becker’s Healthcare Podcast to discuss molecular testing in cancer care

Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.

Learn more
Dr. Dong Chen and Dr. Sounak Gupta join Becker’s Healthcare Podcast to discuss molecular testing in cancer care

Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the right molecular tests for patients, the impact of genetic testing on cancer diagnosis and treatment, and how Mayo Clinic Laboratories is helping physicians make informed decisions for the best patient outcomes.

Focused lung panel informs the use of targeted cancer therapies

Ying-Chun Lo, M.D., Ph.D., explains how Mayo Clinic Laboratories' updated lung panel can better guide clinical decision-making, particularly about targeted lung cancer therapies.

Update on 2021 WHO classification of lung tumors

In this month’s “Hot Topic,” Anja Roden, M.D., discusses new entities and changes of terminology in the 2021 World Health Organization (WHO) classification of lung tumors as well as the nomenclature in small biopsies.

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

(BETA) Choose a language to view this content in:
About the translation.